6 results
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Zevalin
ibritumomab tiuxetan, Lymphoma, Follicular
Date of authorisation: 16/01/2004, Revision: 22, Authorised, Last updated: 09/03/2020Authorised ibritumomab tiuxetan Overview This is a summary … vein) of the active substance ibritumomab tiuxetan. What is Zevalin used for … active substance in Zevalin, ibritumomab, is a monoclonal antibody … -
List item
Human medicine European public assessment report (EPAR): Yttriga
yttrium (90Y) chloride, Radionuclide Imaging
Date of authorisation: 19/01/2006, Revision: 10, Authorised, Last updated: 29/01/2021 -
List item
Human medicine European public assessment report (EPAR): Carmustine Obvius
carmustine, Hodgkin Disease, Lymphoma, Non-Hodgkin
Date of authorisation: 18/07/2018,
, Revision: 5, Authorised, Last updated: 21/10/2020
-
List item
Human medicine European public assessment report (EPAR): Lympreva
dasiprotimut-t, Lymphoma, Non-Hodgkin
Date of refusal: 03/07/2015,
, Refused, Last updated: 17/07/2015
-
List item
Human medicine European public assessment report (EPAR): Gazyvaro
Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014,
, , Revision: 11, Authorised, Last updated: 29/01/2021
-
List item
Referral: Levact
bendamustine, associated names: Ribomustin, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 18/03/2010, EC decision date: 07/07/2010, Last updated: 08/09/2011